Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...
IDT and Ansa are joining forces to empower customers with sequence-perfect constructs up to 50 kb, expanding IDT's synthetic ...
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial and development strategy. The ...
Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, announced that it ...
Zacks Investment Research on MSN
Qiagen (QGEN) is a top-ranked momentum stock: Should you buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform ...
Changes in genes have been linked to the development of different diseases for a while. However, it's not exactly clear what ...
A research team at The University of Osaka revealed that the loss of heterochromatin can cause a chain reaction leading to ...
Researchers at the Indian Institute of Science (IISc), with collaborators from the Institute of Mathematical Sciences (IMSc), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback